Core Insights - GT Biopharma, Inc. is a clinical stage immuno-oncology company focused on developing therapeutics based on its proprietary TriKE platform, which enhances the cancer-killing abilities of natural killer cells [1][3] - Michael Breen, the Executive Chairman and CEO, will participate in the Centurion One Capital 3rd Annual Bahamas Summit on October 28-29, 2025 [1] - The company will be available for one-on-one meetings at the conference, indicating an opportunity for potential investors to engage directly [2] Company Overview - GT Biopharma is dedicated to the development and commercialization of immuno-oncology therapeutic products utilizing the TriKE NK cell engager platform [3] - The company holds an exclusive worldwide license agreement with the University of Minnesota for the development and commercialization of therapies using TriKE technology [3] - For further information, the company directs interested parties to its website [3]

Core Insights - GT Biopharma, Inc. has appointed Hilary Kramer to its Board of Directors, replacing Bruce Wendel who is resigning [1][2] - The company is focused on developing innovative therapeutics based on its proprietary TriKE natural killer (NK) cell engager platform [1][4] - Hilary Kramer brings extensive experience in investment and strategic operations, having previously managed a $12 billion family office portfolio and served on multiple public company boards [2][3] Company Overview - GT Biopharma is a clinical stage biopharmaceutical company specializing in immuno-oncology therapeutic products [4] - The TriKE platform is designed to enhance the cancer-killing abilities of a patient's immune system's natural killer cells [4] - The company holds an exclusive worldwide license agreement with the University of Minnesota for the development and commercialization of therapies using TriKE technology [4]

Core Insights - GT Biopharma, Inc. is a clinical stage immuno-oncology company focused on developing therapeutics based on its proprietary TriKE NK cell engager platform [1][4] - Dr. Jeffrey Miller from the University of Minnesota will present at the 10th Anniversary of the Innate Killer Summit, discussing the advantages of tri-specific engagers in enhancing NK cell activity [2] Company Developments - GTB-3650, a second-generation TriKE, is currently in a Phase 1 dose escalation study for patients with hematological malignancies, with enrollment proceeding as expected [3] - The study will evaluate GTB-3650 in approximately 14 patients with relapsed or refractory CD33 expressing hematologic malignancies, including refractory acute myeloid leukemia and high-risk myelodysplastic syndrome [3] - Initial data from the GTB-3650 study is anticipated to be shared in 2025 [3] Technology and Collaboration - The TriKE platform is designed to enhance the cancer-killing abilities of natural killer cells in patients [4] - GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to develop and commercialize therapies using TriKE technology [4]